HAEMONETICS CORP
Company Stats
- Market Cap
- $4.8B
- as of Sep 30, 2026
- Enterprise Value
- $5.8B
- Shares Outstanding
- 45.5M
- Free Float
- 98.0%
Income Statement
- Revenue
- $1.3B
- Operating Income
- $156.7M
- Net Income
- $97.3M
- EBITDA
- $217.9M
- Non-cash Impairment
- $86.5M
- Revenue Growth, 3Y
- 4.5%
- FCF Margin, 3Y Avg
- 13.7%
- FCF Margin, Worst Year
- 10.5%
Cash Flow
- Free Cash Flow
- $260.4M
- FCF Yield
- 5.4%
- Owner FCF Yield
- 4.7%
Balance Sheet
- Cash & Equivalents
- $245.4M
- Total Debt
- $1.2B
- Net Debt
- $979.1M
- Net Debt / EBITDA
- 4.49x
- EV / EBITDA
- 26.48x
- Net Debt / EBIT
- 6.25x
Returns & Capital
- Share Repurchases
- $175.0M
- Buyback Yield, 3Y Avg
- 2.8%
- SBC, 3Y Avg
- $30.6M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2026 | $1.3B | $260.4M | 19.5% |
| FY2025 | $1.4B | $142.4M | 10.5% |
| FY2024 | $1.3B | $143.6M | 11.0% |
| FY2023 | $1.2B | $81.7M | 7.0% |
| FY2022 | $993.2M | $75.8M | 7.6% |
Annual filing data through FY ended March 28, 2026; shares and float as of November 7, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back
Input Costs Squeeze Margins Even as Demand Holds Firm